Work

LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.583

Authors: J-Y. Shih, J. Wang, Y. Wang, J. Wang, S-H. Lee, K. Azuma, T. Takahashi, J-L. Tan, C.C. Lin, S. Ganguly, V.H.F. Lee, P-L. Chu, S. Shah, B. Diorio, J.M. Bauml, B.C. Cho

Institutions: National Taiwan University Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University Shanghai Cancer Center, Sichuan University, West China Hospital of Sichuan University, Samsung Medical Center, Sungkyunkwan University, Kurume University, Shizuoka Cancer Center, University of Malaya, National Cheng Kung University, Tata Medical Center, University of Hong Kong, Janssen Research & Development (United States), Yonsei University, Yonsei Cancer Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Takeda Pharmaceutical Company, Regeneron Pharmaceuticals, BeiGene, Yuhan, Lunit, Ono Pharmaceutical, Orient Europharma, LG Chem, Pfizer Japan, Chugai Pharmaceutical, MSD K.K., Eli Lilly Japan, Janssen Pharmaceuticals

OpenAlex ID: W4389280271

Cites:

Cited by: 1

Related to: 10